There is a better way — moving beyond the patents vs access debate: A Guest commentary

The debate about whether to suspend patent rights for COVID vaccines doesn’t need to be an “us vs. them” battle that pits access against innovation. Drawing on our previous work for Gilead, we propose a scenario that can create a win for patients, companies and countries.

We are currently in the throes of the latest iteration of a global debate about patent rights that has reared its head regularly over the past decades, a debate in which people take sides stridently and viscerally. Yet, in a surprising move, the Biden administration announced this week that it is willing to negotiate an arrangement via the World Trade Organization in Geneva to make such a thing possible. ...